Evidence map›Paper›PMID 38882660›Full record

ArticleFrontiers in medicine2024

Most accurate mutations in SARS-CoV-2 genomes identified in Uzbek patients show novel amino acid changes.

Mirzakamol S Ayubov, Mukhammadjon K Mirzakhmedov, Abdurakhmon N Yusupov, Akmal M Asrorov, Bakhtiyor V Nosirov, Dilshod E Usmanov, Shukhrat E Shermatov, Khurshida A Ubaydullaeva, Abdusattor Abdukarimov, Zabardast T Buriev and 1 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mirzakamol S AyubovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Mukhammadjon K MirzakhmedovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Abdurakhmon N YusupovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Akmal M AsrorovDepartment of Chemistry for Natural Substances, National University of Uzbekistan, Tashkent, Uzbekistan.
Bakhtiyor V NosirovLuxembourg Institute of Health, Strassen, Luxembourg.
Dilshod E UsmanovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Shukhrat E ShermatovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Khurshida A UbaydullaevaCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Abdusattor AbdukarimovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Zabardast T BurievCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.
Ibrokhim Y AbdurakhmonovCenter of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Republic of Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The rapid changes in the coronavirus genomes created new strains after the first variation was found in Wuhan in 2019. SARS-CoV-2 genotypes should periodically undergo whole genome sequencing to control it because it has been extremely helpful in combating the virus. Many diagnoses, treatments, and vaccinations have been developed against it based on genome sequencing. With its practical implications, this study aimed to determine changes in the delta variant of SARS-CoV-2 widespread in Uzbekistan during the pandemic by genome sequencing, thereby providing crucial insights for developing effective control strategies that can be directly applied in the field. Design: We meticulously generated 17 high-quality whole-genome sequence data from 48 SARS-CoV-2 genotypes of COVID-19 patients who tested positive by PCR in Tashkent, Uzbekistan. Our rigorous approach, which includes stringent quality control measures and multiple rounds of verification, ensures the accuracy and reliability of our findings. Methods: Our study employed a unique combination of genome sequencing and bioinformatics web tools to analyze amino acid (AA) changes in the virus genomes. This approach allowed us to understand the genetic changes in the delta variant of SARS-CoV-2 widespread in Uzbekistan during the pandemic. Results: Our study revealed significant nucleotide polymorphisms, including non-synonymous (missense) and synonymous mutations in the coding regions of the sequenced sample genomes. These findings, categorized by phylogenetic analysis into the G clade (or GK sub-clade), contribute to our understanding of the delta variant of SARS-CoV-2 widespread in Uzbekistan during the pandemic. A total of 134 mutations were identified, consisting of 65 shared and 69 unique mutations. These nucleotide changes, including one frameshift mutation, one conservative and disruptive insertion-deletion, four upstream region mutations, four downstream region mutations, 39 synonymous mutations, and 84 missense mutations, are crucial in the ongoing battle against the virus. Conclusion: The comprehensive whole-genome sequencing data presented in this study aids in tracing the origins and sources of circulating SARS-CoV-2 variants and analyzing emerging variations within Uzbekistan and globally. The genome sequencing of SARS-CoV-2 from samples collected in Uzbekistan in late 2021, during the peak of the pandemic's second wave nationwide, is detailed here. Following acquiring these sequences, research efforts have focused on developing DNA and plant-based edible vaccines utilizing prevalent SARS-CoV-2 strains in Uzbekistan, which are currently undergoing clinical trials.

Indexed as

AA mutationsdelta strainSARS-CoV-2transmissionvirus

Identifiers

PMID38882660
PMCPMC11176497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.